Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...
A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...
A court in Baltimore has ordered Johnson & Johnson to pay $1.56 billion to a Maryland woman who claimed that her use of the company’s baby powder caused her cancer. It is the largest award ever ...
Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...
When looking back at one of the most disruptive years in biopharma in recent memory, sev | Drug pricing, layoffs, personnel moves and other topics drove reader interest all year long. Here's a look at ...
Novo Nordisk wins FDA approval for Wegovy in a pill, introducing first oral GLP-1 option for obesity
After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...
Pharma's end-of-year dealmaking flurry is not showing signs of slowing, as, now, two Japanese drugmakers have joined the ...
Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...
Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease ...
Incog BioPharma, a sterile injectables CDMO, plans to shell out around $200 million to boost production capacity at its ...
Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the South San Francisco biotech its first U.S. nod since its 1997 founding. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback